Researchers have discovered that by combining data from tumor biomarkers, ultrasound and ultrasound-guided diffuse optical tomography (DOT) after a patient's first cycle of chemotherapy it is possible to accurately predict how the tumor is responding to treatment.
E-Mail
IMAGE: Quing Zhu s lab developed this handheld ultrasound-guided diffuse optical tomography system which consists of a 10-centimeter probe and a near-infrared system that takes data noninvasively from the breast from nine. view more
Credit: (Quing Zhu lab)
While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patient s quality of life.
An interdisciplinary team of researchers at Washington University in St. Louis has found that combining data from tumor biomarkers, ultrasound, and ultrasound-guided diffuse optical tomography (DOT) after a patient s first cycle of pre-surgical neoadjuvant chemotherapy provided a highly accurate prediction of how the tumor was responding to the treatment. The results from a clinical trial at Washington University School of Medicine and Ba
Researchers develop tech to predict chemotherapy effectiveness ANI | Updated: Jun 04, 2021 02:06 IST
Washington [US], June 4 (ANI): Combining data from tumor biomarkers, ultrasound, and ultrasound-guided diffuse optical tomography (DOT) after a patient s first cycle of pre-surgical neoadjuvant chemotherapy provided a highly accurate prediction of how the tumor was responding to the treatment, finds an interdisciplinary team of researchers at Washington University in St.Louis.
While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patient s quality of life.
Penn State startup aims to improve treatment of hydrocephalus
Normal pressure hydrocephalus is a disease resulting from too much cerebrospinal fluid around the brain. NPH symptoms are often confused with Alzheimer’s disease but in many cases are reversible with the placement of a shunt. The HydroFix shunt developed by Penn State researchers is designed to mitigate the risks associated with the current shunts on the market and provide a durable treatment solution for NPH patients.Image: Penn State
Penn State startup aims to improve treatment of hydrocephalus
May 28, 2021
UNIVERSITY PARK, Pa. Normal pressure hydrocephalus (NPH) is a disease resulting from too much cerebrospinal fluid (CSF) around the brain and affects roughly 750,000 Americans, typically those over 65 years old. Symptoms are often confused with Alzheimer’s disease, but in many cases they are reversible with the placement of a shunt.
Multi-institutional team combined expertise to make discovery
May 17, 2021 SHARE
Dozens of commonly used drugs, including antibiotics, anti-nausea and anticancer medications, have a potential side effect of lengthening the electrical event that triggers contraction, creating an irregular heartbeat, or cardiac arrhythmia called acquired Long QT syndrome. While safe in their current dosages, some of these drugs may have a more therapeutic benefit at higher doses, but are limited by the risk of arrhythmia.
Through both computational and experimental validation, a multi-institutional team of researchers has identified a compound that prevents the lengthening of the heart’s electrical event, or action potential, resulting in a major step toward safer use and expanded therapeutic efficacy of these medications when taken in combination.